Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
75.93
+2.65 (3.62%)
Jan 14, 2026, 4:00 PM EST - Market closed
Inhibrx Biosciences Employees
As of December 31, 2024, Inhibrx Biosciences had 161 total employees, including 156 full-time and 5 part-time employees. The number of employees decreased by 11 or -6.40% compared to the previous year.
Employees
161
Change (1Y)
-11
Growth (1Y)
-6.40%
Revenue / Employee
$8,696
Profits / Employee
-$963,267
Market Cap
1.10B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 161 | -11 | -6.40% |
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INBX News
- 1 day ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 21 days ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 4 weeks ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 2 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 2 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 2 months ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters
- 2 months ago - Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire